Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Alnylam Pharmaceuticals (NQ: ALNY ) 273.91 +7.32 (+2.75%) Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Alnylam Pharmaceuticals < Previous 1 2 3 4 5 6 7 8 9 ... 15 16 Next > Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity February 15, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Earnings Scheduled For February 15, 2024 February 15, 2024 Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million. Via Benzinga Alnylam Pharmaceuticals's Earnings Outlook February 14, 2024 Via Benzinga (ALNY) - Analyzing Alnylam Pharmaceuticals's Short Interest February 06, 2024 Via Benzinga Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2023 Financial Results January 29, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Analyst Expectations for Alnylam Pharmaceuticals's Future December 08, 2023 Via Benzinga Expert Ratings for Alnylam Pharmaceuticals November 15, 2023 Via Benzinga Earnings Outlook For Alnylam Pharmaceuticals November 01, 2023 Via Benzinga Here's Why Regeneron Pharmaceuticals Just Hit A Record High — Again January 12, 2024 There's more to like about Regeneron Pharmaceuticals than just Eylea, says one analyst. Via Investor's Business Daily Alnylam CEO Yvonne Greenstreet Named 2024 Woman of the Year by Healthcare Businesswomen’s Association January 09, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Alnylam Announces Preliminary* Fourth Quarter and Full Year 2023 Global Net Product Revenues and Provides Additional Updates January 07, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire 2024 And Beyond – Exploring Six Investment Megatrends With Tema ETFs January 04, 2024 A recent report from Tema ETFs, a leader in active exchange-traded funds (ETFs), offers a window into six emerging long-term megatrends. Its analysis provides a detailed account of evolving sectors,... Via Benzinga Topics ETFs 10 Health Care Stocks Whale Activity In Today's Session January 02, 2024 Via Benzinga Alnylam to Webcast Presentation at 42nd Annual J.P. Morgan Healthcare Conference January 02, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Top Biotech Picks For 2024: Piper Sandler Foresees Potential Sector Comeback December 29, 2023 Piper Sandler sees potential turnaround for Biotech sector in 2024, identifies thee top stocks; Arrowhead, Legend Biotech & Alnylam Pharmaceuticals. Via Benzinga Pricing Projections And Market Potential For Ionis' Newly Approved Nerve Damage Drug - Analyst Sees Over $700M Potential December 22, 2023 Friday, the FDA approved AstraZeneca Plc (NASDAQ: AZN) and Ionis Pharmaceuticals Inc's (NASDAQ: IONS) Wainua (eplontersen) for polyneuropathy (nerve damage) of hereditary transthyretin-mediated am Via Benzinga Exposures Product Safety Alnylam Highlights Significant Progress with Platform Innovation and Clinical Pipeline at R&D Day December 13, 2023 From Alnylam Pharmaceuticals, Inc. Via Business Wire 3 biotech powerhouses poised to thrive amid sector rebound December 08, 2023 If the newfound support and uptrend in the biotech sector last, as the new year quickly approaches, the biotech sector could shift from lagger to leader. Via MarketBeat Topics ETFs Alnylam to Webcast Virtual R&D Day December 06, 2023 From Alnylam Pharmaceuticals, Inc. Via Business Wire Why Newly Listed Korro Bio Shares Are Gaining Today December 04, 2023 H.C. Wainwright initiated coverage on Korro Bio Inc (NASDAQ: KRRO), a biotech company developing genetic medicines focused on editing ribonucleic acid (RNA) to treat various diseases. Via Benzinga Alnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2023 November 30, 2023 From Alnylam Pharmaceuticals, Inc. Via Business Wire Alnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular Risk November 11, 2023 From Alnylam Pharmaceuticals, Inc. Via Business Wire Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shareholder Alert: Investigation over Possible Violations of Securities Laws November 08, 2023 San Diego, CA -- (SBWIRE) -- 11/08/2023 -- Alnylam Pharmaceuticals, Inc is under investigation over potential securities laws violations in connection with certain financial statements. Via SBWire Alnylam to Webcast Presentations at Upcoming November Investor Conferences November 07, 2023 From Alnylam Pharmaceuticals, Inc. Via Business Wire Alnylam Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Period Activity November 02, 2023 From Alnylam Pharmaceuticals, Inc. Via Business Wire Alnylam Recognized by Science Magazine as Top Employer for Fifth Consecutive Year October 26, 2023 From Alnylam Pharmaceuticals, Inc. Via Business Wire Alnylam Announces Publication of Results from APOLLO-B Phase 3 Study of Patisiran in Patients with the Cardiomyopathy of ATTR Amyloidosis in the New England Journal of Medicine October 25, 2023 From Alnylam Pharmaceuticals, Inc. Via Business Wire Alnylam Reports Additional Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy October 25, 2023 From Alnylam Pharmaceuticals, Inc. Via Business Wire Alnylam to Webcast Conference Call Discussing Third Quarter 2023 Financial Results October 19, 2023 From Alnylam Pharmaceuticals, Inc. Via Business Wire Intellia Stumbles As It Aims For A First-Ever In CRISPR Gene Editing October 18, 2023 The company can begin a pivotal study of its treatment for cardiomyopathy. Via Investor's Business Daily < Previous 1 2 3 4 5 6 7 8 9 ... 15 16 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
